Author

J. Bridgewater

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Adjuvant chemotherapy with cisplatin and gemcitabine compared to standard of care after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1/AIO-HEP-0112 trial).

BACKGROUND Despite curative resection and adjuvant capecitabine, about 50% of biliary tract cancer (BTC) patients have tumour recurrence or die within two years. Combination chemotherapy with cisplatin and gemcitabine (CisGem) is an established palliative chemotherapy regimen BTC, which has been evaluated in the adjuva...

A. Stein, J. Bridgewater, H. Klümpen et al. · Annals of Oncology · 0 citations

Review Open access Oct 2026

A pivotal Phase 2 study of derazantinib for previously-treated, locally advanced or metastatic cholangiocarcinoma with FGFR2 aberrations: FIDES-01.

BACKGROUND AIMS To evaluate safety and efficacy of FGFR1-3 kinase inhibitor derazantinib, in advanced intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 fusions or rearrangements (FGFR2F), mutations (FGFR2M), or amplifications (FGFR2A), previously treated with chemotherapy. APPROACH RESULTS Open-label, non-contro...

M. Borad, Michele Droz Dit Busset, M. Javle et al. · Hepatology · 0 citations